TN-401 Gene Therapy Significantly Reduces Arrhythmias in Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: Newsfilter
- Clinical Trial Results: In the RIDGE-1 clinical trial, TN-401 gene therapy achieved an average 64% reduction in premature ventricular contractions (PVCs) among six patients, demonstrating the therapy's potential to transform current treatment paradigms for arrhythmias.
- Safety Assessment: TN-401 was well tolerated at both 3E13 vg/kg and 6E13 vg/kg doses, with all patients successfully tapering off immunosuppressants and no serious adverse events reported, indicating the therapy's safety and feasibility.
- Biomarker Evidence: Post-dose biopsies revealed effective transduction and expression of TN-401 in heart muscle cells, with DNA levels of 3.4 vg/dg and 3.8 vg/dg in Cohorts 1 and 2 respectively, further supporting its scientific basis for clinical application.
- Regulatory Recognition: The European Medicines Agency has granted TN-401 PRIME designation, highlighting the therapy's potential to address significant unmet medical needs in heart disease patients, which may expedite its path to market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNYA
Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.799
Low
2.00
Averages
9.14
High
40.00
Current: 0.799
Low
2.00
Averages
9.14
High
40.00
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
TN-401 Gene Therapy Significantly Reduces Arrhythmias in Patients
- Clinical Trial Results: In the RIDGE-1 clinical trial, TN-401 gene therapy achieved an average 64% reduction in premature ventricular contractions (PVCs) among six patients, demonstrating the therapy's potential to transform current treatment paradigms for arrhythmias.
- Safety Assessment: TN-401 was well tolerated at both 3E13 vg/kg and 6E13 vg/kg doses, with all patients successfully tapering off immunosuppressants and no serious adverse events reported, indicating the therapy's safety and feasibility.
- Biomarker Evidence: Post-dose biopsies revealed effective transduction and expression of TN-401 in heart muscle cells, with DNA levels of 3.4 vg/dg and 3.8 vg/dg in Cohorts 1 and 2 respectively, further supporting its scientific basis for clinical application.
- Regulatory Recognition: The European Medicines Agency has granted TN-401 PRIME designation, highlighting the therapy's potential to address significant unmet medical needs in heart disease patients, which may expedite its path to market.
See More
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
TN-401 Gene Therapy Significantly Reduces Arrhythmias in Patients
- Clinical Trial Results: In the RIDGE-1 clinical trial, TN-401 gene therapy achieved an average 64% reduction in premature ventricular contractions (PVCs) among six patients, demonstrating the therapy's potential to transform current treatment paradigms for arrhythmias.
- Safety Assessment: TN-401 was well tolerated at both 3E13 vg/kg and 6E13 vg/kg doses, with all patients successfully tapering off immunosuppressants and no serious adverse events reported, indicating the therapy's safety and feasibility.
- Biomarker Evidence: Post-dose biopsies revealed effective transduction and expression of TN-401 in heart muscle cells, with DNA levels of 3.4 vg/dg and 3.8 vg/dg in Cohorts 1 and 2 respectively, further supporting its scientific basis for clinical application.
- Regulatory Recognition: The European Medicines Agency has granted TN-401 PRIME designation, highlighting the therapy's potential to address significant unmet medical needs in heart disease patients, which may expedite its path to market.
See More
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
